IntraLinks Announces Adobe-based Paperless Solution for Clinical Trial Process
IntraLinks, a provider of critical information exchange solutions, announced a strategic partnership with Adobe Systems Inc., to develop automated solutions addressing cross-organization data capture and submission based-business processes within the life sciences industry. Specifically, the joint solution is aimed to improve workflow during the site recruitment and study start-up phases of a clinical trial.
Once an electronic form is created using Adobe’s LiveCycle Enterprise Suite (ES), IntraLinks' validated platform manages the external workflow to organize, distribute, collect, and track e-forms across the firewall with email notifications and a "one-click to submit" process. LiveCycle ES completes the process by automatically retrieving the completed forms from IntraLinks and routing them through an internal review and approval process.
“Building on Adobe's LiveCycle ES, IntraLinks will leverage its secure and auditable information exchange platform to create a truly paperless solution for the clinical trials process," said Alison Shurell, vice president, IntraLinks, said in a press release. "This new platform replaces inefficient and non-secure methods of sharing sensitive clinical trial documents such as email, fax and courier."
"Life sciences professionals who already depend on Adobe's LiveCycle ES for data capture and submission based processes will now have a comprehensive solution for document-centric workflows," said Melonie Warfel, Director Worldwide Standards & Life Sciences for Adobe Systems Inc. "Together, Adobe and IntraLinks will work to make clinical trial management an efficient, paper-free process." IntraLinks provides on-demand solutions for businesses in various industries to securely collaborate, communicate and exchange critical information inside and outside the enterprise. For more information on Adobe’s LiveCycle ES for Life Sciences, link here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
